IKBKG anticorps (N-Term)
-
- Antigène Voir toutes IKBKG Anticorps
- IKBKG (Inhibitor of kappa Light Polypeptide Gene Enhancer in B-Cells, Kinase gamma (IKBKG))
-
Épitope
- N-Term
-
Reactivité
- Humain, Souris, Rat, Lapin, Boeuf (Vache), Chien, Cobaye, Cheval, Porc
-
Hôte
- Lapin
-
Clonalité
- Polyclonal
-
Conjugué
- Cet anticorp IKBKG est non-conjugé
-
Application
- Western Blotting (WB)
- Séquence
- MNRHLWKSQL CEMVQPSGGP AADQDVLGEE SPLGKPAMLH LPSEQGAPET
- Homologie
- Cow: 79%, Dog: 93%, Guinea Pig: 85%, Horse: 93%, Human: 100%, Mouse: 86%, Pig: 93%, Rabbit: 86%, Rat: 86%
- Attributs du produit
- This is a rabbit polyclonal antibody against IKBKG. It was validated on Western Blot using a cell lysate as a positive control.
- Purification
- Affinity Purified
- Immunogène
- The immunogen is a synthetic peptide directed towards the N terminal region of human IKBKG
- Top Product
- Discover our top product IKBKG Anticorps primaire
-
-
- Indications d'application
- Optimal working dilutions should be determined experimentally by the investigator.
- Commentaires
-
Antigen size: 419 AA
- Restrictions
- For Research Use only
-
- Format
- Liquid
- Concentration
- Lot specific
- Buffer
- Liquid. Purified antibody supplied in 1x PBS buffer with 0.09 % (w/v) sodium azide and 2 % sucrose.
- Agent conservateur
- Sodium azide
- Précaution d'utilisation
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
- Conseil sur la manipulation
- Avoid repeated freeze-thaw cycles.
- Stock
- -20 °C
- Stockage commentaire
- For short term use, store at 2-8°C up to 1 week. For long term storage, store at -20°C in small aliquots to prevent freeze-thaw cycles.
-
- Antigène
- IKBKG (Inhibitor of kappa Light Polypeptide Gene Enhancer in B-Cells, Kinase gamma (IKBKG))
- Autre désignation
- IKBKG (IKBKG Produits)
- Synonymes
- anticorps AMCBX1, anticorps FIP-3, anticorps FIP3, anticorps Fip3p, anticorps IKK-gamma, anticorps IP, anticorps IP1, anticorps IP2, anticorps IPD2, anticorps NEMO, anticorps ZC2HC9, anticorps 1110037D23Rik, anticorps AI848108, anticorps AI851264, anticorps AW124339, anticorps IKK[g], anticorps Nemo, anticorps nemo, anticorps fj33c07, anticorps wu:fj33c07, anticorps zgc:113492, anticorps MGC97885, anticorps IKBKG, anticorps IKBKG_1, anticorps IKBKG_2, anticorps CG16910, anticorps DmIKK-gamma, anticorps DmIKKgamma, anticorps Dmel\\CG16910, anticorps Dmikkgamma, anticorps IKK, anticorps IKK[[gamma]], anticorps IKKg, anticorps IKKgamma, anticorps KEY, anticorps Kenny, anticorps Key, anticorps dIKK, anticorps dIKK-gamma, anticorps dmIKKgamma, anticorps inhibitor of nuclear factor kappa B kinase subunit gamma, anticorps inhibitor of kappaB kinase gamma, anticorps inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase gamma, anticorps inhibitor of nuclear factor kappa B kinase subunit gamma L homeolog, anticorps kenny, anticorps IKBKG, anticorps Ikbkg, anticorps ikbkg, anticorps ikbkg.L, anticorps IKBKG_1, anticorps key
- Sujet
-
IKBKG is the regulatory subunit of the IKK core complex which phosphorylates inhibitors of NF-kappa-B thus leading to the dissociation of the inhibitor/NF-kappa-B complex and ultimately the degradation of the inhibitor. IKBKG also considered to be a mediator for TAX activation of NF-kappa-B. IKBKG could be implicated in NF-kappa-B-mediated protection from cytokine toxicity.Familial incontinentia pigmenti (IP) is a genodermatosis that segregates as an X-linked dominant disorder and is usually lethal prenatally in males (The International Incontinentia Pigmenti Consortium, 2000 [PubMed 10839543]). In affected females it causes highly variable abnormalities of the skin, hair, nails, teeth, eyes, and central nervous system. The prominent skin signs occur in 4 classic cutaneous stages: perinatal inflammatory vesicles, verrucous patches, a distinctive pattern of hyperpigmentation, and dermal scarring. Cells expressing the mutated X chromosome are eliminated selectively around the time of birth, so females with IP exhibit extremely skewed X-inactivation. Familial incontinentia pigmenti is caused by mutations in the NEMO gene and is here referred to as IP2, or 'classical' incontinentia pigmenti. Sporadic incontinentia pigmenti, the so-called IP1, which maps to Xp11, is categorized as hypomelanosis of Ito (MIM 300337).[supplied by OMIM]. Sequence Note: removed 1 base from the 5' end that did not align to the reference genome assembly. Publication Note: This RefSeq record includes a subset of the publications that are available for this gene. Please see the Entrez Gene record to access additional publications. PRIMARYREFSEQ_SPAN PRIMARY_IDENTIFIER PRIMARY_SPAN COMP 1-2120 AF261086.1 2-2121
Alias Symbols: AMCBX1, FIP-3, FIP3, Fip3p, IKK-gamma, IP, IP1, IP2, IPD2, NEMO
Protein Interaction Partner: CHUK, IKBKB, ATM, PIAS4, MALT1, TRIM13, BCL10, SUMO1, UBC, TRAF6, MTOR, RPTOR, RELA, NFKBIA, IKBKG, ARHGDIA, RHOA, CDC37, SRC, FYN, FKBP5, FGR, PPP4C, PPP2R1B, LYN, NMRAL1, USP7, ZC3H12A, IRAK1, USP10, RIPK1, SQSTM1, RNF31, PPP1CC, HDLBP, PPFIA1, PSMB8, K
Protein Size: 419 - Poids moléculaire
- 48 kDa
- ID gène
- 8517
- NCBI Accession
- NM_003639, NP_003630
- UniProt
- Q9Y6K9
- Pathways
- Signalisation NF-kappaB, Signalisation RTK, TCR Signaling, Signalisation TLR, Fc-epsilon Receptor Signaling Pathway, Activation of Innate immune Response, M Phase, Production of Molecular Mediator of Immune Response, Hepatitis C, Protein targeting to Nucleus, Toll-Like Receptors Cascades, BCR Signaling, Ubiquitin Proteasome Pathway, S100 Proteins
-